American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

Gastroenterology

Volumn 153, Issue 3, 2017, Pages 835-857.e6

  Vande Casteele, Niels ^a   Herfarth, Hans ^b   Katz, Jeffry ^c   Falck Ytter, Yngve ^c,d   Singh, Siddharth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 MMP; 6 MP; 6 TGN; 6 thioguanine; ADAb; AGA; American Gastroenterological Association; anti drug antibody; AZA; azathioprine; C reactive protein; CBC; CD; CI; complete blood count; confidence interval; Crohn's disease; CRP; ECLIA; electrochemiluminescence immunoassay; ELISA; enzyme linked immunosorbent assay; GRADE; Grading of Recommendations Assessment, Development, and Evaluation; HMSA; homogenous mobility shift assay; IBD; inflammatory bowel disease; radioimmunoassay; randomized controlled trial; RCT; relative risk; RIA; RR; TDM; therapeutic drug monitoring; thiopurine methyltransferase; TNF; TPMT; tumor necrosis factor; UC; ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; GOLIMUMAB; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR INHIBITOR; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; MONOCLONAL ANTIBODY; NUCLEOSIDE; TUMOR NECROSIS FACTOR;

ANTIBODY BLOOD LEVEL; ARTICLE; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFLAMMATORY BOWEL DISEASE; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; INFLAMMATORY BOWEL DISEASES; PROCEDURES;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BODY WEIGHT; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; THIONUCLEOSIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85028868958     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.07.031     Document Type: Article

References (88)

1. Colombel, J.F., Narula, N., Peyrin-Biroulet, L., Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 152 (2017), 351–361.
2. Vande Casteele, N., Feagan, B.G., Gils, A., et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep, 16, 2014, 378.
3. Yarur, A.J., Rubin, D.T., Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 21 (2015), 1709–1718.
4. Afif, W., Loftus, E.V. Jr., Faubion, W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105 (2010), 1133–1139.
5. Dubinsky, M.C., Yang, H., Hassard, P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002), 904–915.
6. Goldberg, R., Irving, P.M., Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 9 (2015), 891–900.
7. Sultan, S., Falck-Ytter, Y., Inadomi, J.M., The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol 11 (2013), 329–332.
8. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
9. Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
10. Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
11. Lee, T.W., Fedorak, R.N., Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 39 (2010), 543–557.
12. Schellekens, H., Casadevall, N., Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:Suppl 2 (2004), II4–II9.
13. Ordas, I., Feagan, B.G., Sandborn, W.J., Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10 (2012), 1079–1087.
14. Papamichael, K., Gils, A., Rutgeerts, P., et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 21 (2015), 182–197.
15. Marini, J.C., Sendecki, J., Cornillie, F., et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®. AAPS J 19 (2017), 161–171.
16. European Medicines Agency. Guideline on Bioanalytical Method Validation. 2009, European Medicine Agency, London.
17. US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation., 2013, US Food and Drug Administration, Silver Spring, MD.
18. Steenholdt, C., Ainsworth, M.A., Tovey, M., et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Therapeutic Drug Monitor 35 (2013), 530–538.
19. Martin, S., del Agua, A.R., Torres, N., et al. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med 53 (2015), e297–e299.
20. Bodini, G., Giannini, E.G., Furnari, M., et al. Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn's disease. J Gastrointes Liver Dis 24 (2015), 451–456.
21. Vande Casteele, N., Khanna, R., Levesque, B.G., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 64 (2015), 1539–1545.
22. Brandse, J.F., Van Den Brink, G.R., Wildenberg, M.E., et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149 (2015), 350–355.
23. Paul, S., Del Tedesco, E., Marotte, H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 19 (2013), 2568–2576.
24. Yanai, H., Lichtenstein, L., Assa, A., et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 13 (2015), 522–530.
25. Roblin, X., Marotte, H., Rinaudo, M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12 (2014), 80–84.
26. Steenholdt, C., Brynskov, J., Thomsen, O., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63 (2014), 919–927.
27. Steenholdt, C., Bendtzen, K., Brynskov, J., et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 46 (2011), 310–318.
28. Khanna, R., Sattin, B.D., Afif, W., et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 38 (2013), 447–459.
29. Davidov, Y., Ungar, B., Bar-Yoseph, H., et al. Association of induction infliximab levels with clinical response in perianal Crohn's disease. J Crohns Colitis 11 (2017), 549–555.
30. Ungar, B., Mazor, Y., Weisshof, R., et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 43 (2016), 1293–1299.
31. Yarur, A.J., Jain, A., Hauenstein, S.I., et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 22 (2016), 409–415.
32. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
33. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
34. Levesque, B.G., Sandborn, W.J., Ruel, J., et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 148 (2015), 37–51 e1.
35. Velayos, F.S., Kahn, J.G., Sandborn, W.J., et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11 (2013), 654–666.
36. Wolf, D., D'Haens, G., Sandborn, W.J., et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 40 (2014), 486–497.
37. Gibson, D.J., Heetun, Z.S., Redmond, C.E., et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 13 (2015), 330–335.
38. Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
39. Vaughn, B.P., Martinez-Vazquez, M., Patwardhan, V.R., et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 20 (2014), 1996–2003.
40. Adedokun, O.J., Sandborn, W.J., Feagan, B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147 (2014), 1296–1307.
41. Reinisch, W., Colombel, J.F., Sandborn, W.J., et al. Factors associated with short- and long-term outcomes oftherapy for crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 539–547.
42. Sharma, S., Eckert, D., Hyams, J.S., et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis 21 (2015), 783–792.
43. Cornillie, F., Hanauer, S.B., Diamond, R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 63 (2014), 1721–1727.
44. Williet, N., Boschetti, G., Fovet, M., et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases with need for additional doses within 6 months. Clin Gastroenterol Hepatol, 2016 Nov 24 pii: S1542–3565(16)31121-1 http://dx.doi.org/10.1016/j.cgh.2016.11.023 [Epub ahead of print].
45. Adedokun, O.J., Xu, Z., Marano, C.W., et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis 11 (2017), 35–46.
46. Warman, A., Straathof, J.W.A., Derijks, L.J.J., Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol 27 (2015), 242–248.
47. Arias, M.T., Vande Casteele, N., Vermeire, S., et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 13 (2015), 531–538.
48. Bortlik, M., Duricova, D., Malickova, K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 7 (2013), 736–743.
49. Singh, N., Rosenthal, C.J., Melmed, G.Y., et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 1708–1713.
50. Mazor, Y., Almog, R., Kopylov, U., et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 40 (2014), 620–628.
51. Ward, M.G., Kariyawasam, V.C., Mogan, S.B., et al. Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 28 (2013), 100–101.
52. Steenholdt, C., Frederiksen, M.T., Bendtzen, K., et al. Time course and clinical implications of development of binding and neutralizing antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol 50 (2016), 483–489.
53. Frederiksen, M.T., Ainsworth, M.A., Brynskov, J., et al. Antibodies against infliximab (IFX) are associated with de novo development of antibodies to adalimumab (ADL) and therapeutic failure in IFX-to-ADL switchers with inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 1714–1721.
54. Chaparro, M., Guerra, I., Iborra, M., et al. Correlation between adalimumab serum levels and remission after the induction phase in crohn's disease patients. Gastroenterology 148 (2015), S107–S108.
55. Vande Casteele, N., Feagan, B., Vermeire, S., et al. Covariates influencing the exposure-response relationship for certolizumab pegol during the induction and maintenances phases in patients with Crohn's disease. Am J Gastroenterol 111 (2016), S262–S263.
56. Detrez, I., Dreesen, E., Van Stappen, T., et al. Variability in golimumab exposure: a 'real-life' observational study in active ulcerative colitis. J Crohns Colitis 10 (2016), 575–581.
57. Vande Casteele, N., Gils, A., Singh, S., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108 (2013), 962–971.
58. Ungar, B., Anafy, A., Yanai, H., et al. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 21 (2015), 1907–1914.
59. Ungar, B., Chowers, Y., Yavzori, M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 63 (2014), 1258–1264.
60. Baert, F., Noman, M., Vermeire, S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003), 601–608.
61. Dewit, O., Moreels, T., Baert, F., et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem 44 (2011), 1062–1066.
62. Lennard, L., Implementation of TPMT testing. Br J Clin Pharmacol 77 (2014), 704–714.
63. Booth, R.A., Ansari, M.T., Loit, E., et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 154 (2011), 814–823 W-295-8.
64. Colombel, J., Ferrari, N., Debuysere, H., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118 (2000), 1025–1030.
65. Lewis, J.D., Abramson, O., Pascua, M., et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 7 (2009), 1195–1201.
66. Food and Drug Administration. Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee. 2003, Food and Drug Administration, Silver Spring, MD.
67. Osterman, M.T., Kundu, R., Lichtenstein, G.R., et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130 (2006), 1047–1053.
68. Moreau, A.C., Paul, S., Del Tedesco, E., et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis 20 (2014), 464–471.
69. Coenen, M.J.H., De Jong, D.J., Van Marrewijk, C.J., et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology 149 (2015), 907–917.
70. Newman, W.G., Payne, K., Tricker, K., et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 12 (2011), 815–826.
71. Sayani, F.A., Prosser, C., Bailey, R.J., et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol 19 (2005), 147–151.
72. Roy, L.M., Zur, R.M., Uleryk, E., et al. Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics 17 (2016), 633–656.
73. Takatsu, N., Matsui, T., Murakami, Y., et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 24 (2009), 1258–1264.
74. Mottet, C., Schoepfer, A.M., Juillerat, P., et al. Experts opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease. Inflamm Bowel Dis 22 (2016), 2733–2747.
75. Thompson, A.J., Newman, W.G., Elliott, R.A., et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health 17 (2014), 22–33.
76. Haines, M.L., Ajlouni, Y., Irving, P.M., et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 17 (2011), 1301–1307.
77. Yarur, A.J., Kubiliun, M.J., Czul, F., et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 13 (2015), 1118–1124.
78. Cuffari, C., Hunt, S., Bayless, T., Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48 (2001), 642–646.
79. Goldberg, R., Moore, G., Cunningham, G., et al. Thiopurine metabolite testing in inflammatory bowel disease. J Gastroenterol Hepatol 31 (2016), 553–560.
80. Kennedy, N.A., Asser, T.L., Mountifield, R.E., et al. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern Med J 43 (2013), 278–286.
81. Mardini, H.E., Arnold, G.L., Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 36 (2003), 390–395.
82. Smith, M., Blaker, P., Patel, C., et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 67 (2013), 161–169.
83. Dassopoulos, T., Dubinsky, M.C., Bentsen, J.L., et al. Randomised clinical trial: individualised vs weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 39 (2014), 163–175.
84. Reinshagen, M., Schütz, E., Armstrong, V.W., et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 53 (2007), 1306–1314.
85. Van Asseldonk, D.P., Sanderson, J., de Boer, N.K.H., et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—Proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis 43 (2011), 270–276.
86. Pavlidis, P., Stamoulos, P., Abdulrehman, A., et al. Long-term safety and efficacy of low-dose azathioprine and allopurinol cotherapy in inflammatory bowel disease: a large observational study. Inflamm Bowel Dis 22 (2016), 1639–1646.
87. Hoentjen, F., Seinen, M.L., Hanauer, S.B., et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 19 (2013), 363–369.
88. Bendtzen, K., Steenholdt, C., Thomsen, O.Ø., et al. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-TNF-alpha antibodies. Scand J Gastroenterol 44 (2009), 774–781.